Filing Flows › TherapeuticsMD (TXMD) › Q1 2025
TherapeuticsMD (TXMD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
TherapeuticsMD (TXMD) reported revenue of $393K for the first quarter 2025 (Q1 2025), +26% from a year earlier and -41% from the quarter before. Operating margin was -221.6%, net loss $653K (166.2% of revenue).
TherapeuticsMD, Q1 2025: revenue $393K (+26% year over year), operating margin -221.6%, net loss $653K, operating cash flow $699K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $393K | -41% | +26% |
| Operating profit | −$871K | — | — |
| Net earnings | −$653K | -359% | — |
| Operating cash flow | $699K | 41× | — |
What changed
Revenue was $393K in Q1 2025, up 26% year over year and down 41% from the previous quarter.
Operating costs exceeded revenue by $871K, an operating margin of -221.6%. Total costs fell 13% while revenue rose 26%. The fastest-growing cost line was Other operating costs (+38%). The quarter ended with a net loss of $653K, after a profit of $252K the previous quarter. Non-operating items added $186K, -27% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $699K. Non-cash charges added back $95K of depreciation and amortization and $23K of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $12.1M exceeded it, leaving free cash flow of −$11.4M.
Questions
What was TherapeuticsMD's revenue in the first quarter 2025?
TherapeuticsMD (TXMD) reported revenue of $393K for the first quarter 2025 (Q1 2025), +26% from a year earlier and -41% from the quarter before.
Was TherapeuticsMD profitable in the first quarter 2025?
Operating loss was $871K (-221.6% of revenue) and net loss $653K.
Source: TherapeuticsMD 10-Q on SEC EDGAR.